PMID- 27235082
OWN - NLM
STAT- MEDLINE
DCOM- 20171019
LR  - 20240326
IS  - 1873-7528 (Electronic)
IS  - 0149-7634 (Print)
IS  - 0149-7634 (Linking)
VI  - 70
DP  - 2016 Nov
TI  - Adolescence as a period of vulnerability and intervention in schizophrenia: 
      Insights from the MAM model.
PG  - 260-270
LID - S0149-7634(16)30097-5 [pii]
LID - 10.1016/j.neubiorev.2016.05.030 [doi]
AB  - Adolescence is a time of extensive neuroanatomical, functional and chemical 
      reorganization of the brain, which parallels substantial maturational changes in 
      behavior and cognition. Environmental factors that impinge on the timing of these 
      developmental factors, including stress and drug exposure, increase the risk for 
      psychiatric disorders. Indeed, antecedents to affective and psychotic disorders, 
      which have clinical and pathophysiological overlap, are commonly associated with 
      risk factors during adolescence that predispose to these disorders. In the 
      context of schizophrenia, psychosis typically begins in late adolescence/early 
      adulthood, which has been replicated by animal models. Rats exposed during 
      gestational day (GD) 17 to the mitotoxin methylazoxymethanol acetate (MAM) 
      exhibit behavioral, pharmacological, and anatomical characteristics consistent 
      with an animal model of schizophrenia. Here we provide an overview of adolescent 
      changes within the dopamine system and the PFC and review recent findings 
      regarding the effects of stress and cannabis exposure during the peripubertal 
      period as risk factors for the emergence of schizophrenia-like deficits. Finally, 
      we discuss peripubertal interventions appearing to circumvent the emergence of 
      adult schizophrenia-like deficits.
CI  - Copyright (c) 2016 Elsevier Ltd. All rights reserved.
FAU - Gomes, Felipe V
AU  - Gomes FV
AD  - Departments of Neuroscience, Psychiatry and Psychology, United States.
FAU - Rincon-Cortes, Millie
AU  - Rincon-Cortes M
AD  - Departments of Neuroscience, Psychiatry and Psychology, United States.
FAU - Grace, Anthony A
AU  - Grace AA
AD  - Departments of Neuroscience, Psychiatry and Psychology, United States. Electronic 
      address: GraceAA@pitt.edu.
LA  - eng
GR  - R01 MH057440/MH/NIMH NIH HHS/United States
GR  - R21 MH104320/MH/NIMH NIH HHS/United States
GR  - R37 MH057440/MH/NIMH NIH HHS/United States
GR  - T32 MH016804/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20160524
PL  - United States
TA  - Neurosci Biobehav Rev
JT  - Neuroscience and biobehavioral reviews
JID - 7806090
RN  - 592-62-1 (Methylazoxymethanol Acetate)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Adolescent
MH  - Animals
MH  - Brain
MH  - Disease Models, Animal
MH  - Dopamine
MH  - Humans
MH  - Methylazoxymethanol Acetate
MH  - Rats
MH  - *Schizophrenia
PMC - PMC5074867
MID - NIHMS793936
OTO - NOTNLM
OT  - *Adolescence
OT  - *Animal models
OT  - *Cannabinoids
OT  - *Development
OT  - *Dopamine
OT  - *Schizophrenia
OT  - *Stress
COIS- AAG has received funds from Johnson & Johnson, Lundbeck, Pfizer, GSK, Merck, 
      Takeda, Dainippon Sumitomo, Otsuka, Lilly, Roche, Asubio, Abbott, Autofony, and 
      Janssen. FVG and MRC declare no conflict of interest.
EDAT- 2016/10/22 06:00
MHDA- 2017/10/20 06:00
PMCR- 2017/11/01
CRDT- 2016/05/29 06:00
PHST- 2016/02/23 00:00 [received]
PHST- 2016/05/24 00:00 [revised]
PHST- 2016/05/24 00:00 [accepted]
PHST- 2016/10/22 06:00 [pubmed]
PHST- 2017/10/20 06:00 [medline]
PHST- 2016/05/29 06:00 [entrez]
PHST- 2017/11/01 00:00 [pmc-release]
AID - S0149-7634(16)30097-5 [pii]
AID - 10.1016/j.neubiorev.2016.05.030 [doi]
PST - ppublish
SO  - Neurosci Biobehav Rev. 2016 Nov;70:260-270. doi: 10.1016/j.neubiorev.2016.05.030. 
      Epub 2016 May 24.